secwatch.observer — SEC 8-K summary
======================================

Issuer:     Outlook Therapeutics, Inc. (OTLK)
CIK:        0001649989
Form:       8-K
Filed at:   2026-08-12T20:01:42+00:00
Accession:  0001104659-26-094848
Event type: other_material
Sentiment:  negative
Materiality: 0.80
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Outlook Therapeutics reports $11.2M cash; going concern doubt persists
----------------------------------------------------------------------

- Preliminary cash and cash equivalents of $11.2M as of June 30, 2026 (unaudited).
- Net loss of $62.4M in FY2025; revenue of $1.4M from LYTENAVA sales in Germany/UK.
- Going concern: cash only sufficient into September 2026; need substantial additional capital.
- $19.8M outstanding under Atlas Sciences note due June 2027; 7.5% exit fee on redemptions.
- Terminated ATM prospectus supplement with H.C. Wainwright on Aug 10, 2026; agreement remains.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1649989/000110465926094848/0001104659-26-094848-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1649989/000110465926094848/tm2622278d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-094848

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer